Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas
about
Sialyl-tn in cancer: (how) did we miss the target?Bridging innate and adaptive antitumor immunity targeting glycans.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Cancer vaccines and carbohydrate epitopes.Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.Tumor-Associated Glycans and Immune SurveillanceMUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccinesMUC1 as a target antigen for cancer immunotherapy.Schistosome glycans and innate immunity.Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic miceMultifunctional nanobeacon for imaging Thomsen-Friedenreich antigen-associated colorectal cancerAberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.Immunotherapy for cancer: synthetic carbohydrate-based vaccines.Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.MUC1 immunotherapy.Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.The sweet side of tumor immunotherapy.A Tn antigen binding lectin from Myrsine coriacea displays toxicity in human cancer cell lines.Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells.Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells.Solid-phase synthesis of a pentavalent GalNAc-containing glycopeptide (Tn antigen) representing the nephropathy-associated IgA hinge region.Immune response to Thomsen-Friedenreich disaccharide and glycan engineering.Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention.Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
P2860
Q33649572-BAC6F558-70A0-4066-8BBA-8304C177A7F6Q33960021-E3847DCE-D868-46B7-B13C-F96B8235D3AFQ34494018-460B5AA0-6715-4444-9811-8343CC494D8AQ35525289-D8FF6F82-2D88-4D6A-8605-8ECE28200384Q35657628-3BD85634-030C-40F9-8F7E-6176BAC9DD09Q35890610-9B2E5CF5-8D5E-4B49-B7BD-1CEF6F67518CQ35898801-BE0E76B4-043F-4A80-BB88-733AC15E2909Q36200540-1D346D65-2146-43F8-AF7B-D6419BA5412FQ36238699-4752365B-85A5-4BC0-9331-9E8C86C038CFQ36247352-48AEFD47-5C5D-4A2B-BC16-BE0A65C5C8D4Q36509312-0FDFF36A-FA3A-4FFA-9B9C-AADC57CEB333Q36592454-FBE6673F-78EE-474A-91BE-1717DA2A2FA9Q37290676-EF1186CE-43B4-4BF1-B0FD-2A004EFE406AQ37453814-F7639969-A166-40B9-BE6A-266FB601E474Q37459645-B97FC6A1-8E6B-421D-B2B1-E7E89D1E0D09Q37773241-B714ABD5-27F7-491E-958C-CB1FDB19BC5CQ37851048-E4774C96-1830-430A-B44F-8B930E674FBEQ38031282-D4EB8633-9718-45EC-9919-9CE03CEAC74AQ39340190-72E215AB-A255-4FF6-A474-97D342EB29A6Q39594793-C45C7BA7-CBE5-4EAF-9D1F-36620C0D512FQ40197046-DC56628E-CA14-46BE-9CD6-DA47F30D5C28Q40338018-9D11D659-D88D-46CE-9A37-0E2A1DF9036BQ40440515-2258E25A-3FFB-4F13-BC54-F63B92925E10Q41568866-B8DF0A97-347D-453C-8720-B57216EB57B0Q42426240-CB1AB829-5E57-4458-A186-07A22C9C8973Q46610435-7221F78B-7E42-4294-B79C-D64C4D2D0CCDQ46610438-EB8544E3-081D-45F9-968D-25CC79A8422BQ50908486-5812D091-2D8A-4877-A749-ABBFA346D42B
P2860
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas
@ast
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas
@en
type
label
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas
@ast
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas
@en
prefLabel
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas
@ast
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas
@en
P2093
P2860
P356
P1476
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas
@en
P2093
Alessandra Franco
Sandra J Gendler
P2860
P304
P356
10.1084/JEM.20031865
P407
P577
2004-03-01T00:00:00Z